SCHEMBL3140408

SCHEMBL3140408

O=CCCC(C=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HRH1 P35367 4/20 0.35
AOX1 Q06278 1/20 0.35
HTR2A P28223 4/20 0.33
GABBR2 O75899 2/20 0.33
GABBR1 Q9UBS5 2/20 0.33
KDM4E B2RXH2 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ADH1B P00325 1/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
ADH7 P40394 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28053814 0.87 CYP2D6 (0.42) CYP2D6HRH1HTR2AKDM4EL3MBTL1
SCHEMBL10021802 0.85 GRIN1 (0.34) CYP2D6HRH1HTR2AKCNH2
SCHEMBL6802502 0.84 CYP2C19 (0.42) CYP2D6CYP1A2PKMSMN1; SMN2NPSR1
SCHEMBL7235718 0.80 HRH1 (0.50) CYP2D6CYP1A2SMN1; SMN2NPSR1HRH1
SCHEMBL12825377 0.79 HRH1 (0.56) CYP2D6CYP1A2HRH1HTR2AGABBR2
SCHEMBL21308579 0.79 AOC3 (0.42) CYP2D6SMN1; SMN2HRH1HTR2AKDM4E
SCHEMBL9479770 0.79 CYP2D6 (0.37) CYP2D6HRH1HTR2AKDM4EL3MBTL1
SCHEMBL3685590 0.79 AOC3 (0.42) CYP2D6SMN1; SMN2HRH1HTR2AKDM4E
SCHEMBL13513553 0.79 TRPA1 (0.44) CYP2D6SMN1; SMN2HRH1KDM4EL3MBTL1
SCHEMBL28258029 0.79 HRH1 (0.40) CYP2D6HRH1HTR2AGABBR2GABBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283358-B2 N-sulfonamido polycyclic pyrazolyl compounds ELAN PHARMACEUTICALS, INC. (US) 2012-10-09 US disclosed
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS ELAN PHARMACEUTICALS, INC. 2010-04-01 US disclosed
US-4978530-A Sanitized, disinfected and sporicidal articles, and processes for sanitizing, disinfecting and rendering objects sporicidal HEALTH CARE PRODUCTS, INC. (CA) 1990-12-18 US disclosed
CN-1006386-B PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER SHINETSU CHEM IND CO (JP) 1990-01-10 CN disclosed
CN-85107531-A Process for producing vinyl chloride polymer 1987-01-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081680-A1 N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS PSEN1, PSEN2, SULT1E1 CYP2D6 547/4885CYP1A2 348/4885PKM 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.